Page 84 - Read Online

Page 22 of 24 Tokuyasu et al. J Cancer Metastasis Treat 2018;4:2 I http://dx.doi.org/10.20517/2394-4722.2017.52

173. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
+
174. Accolla RS, Tosi G. Optimal MHC-II-restricted tumor antigen presentation to CD4 T helper cells: the key issue for development of
anti-tumor vaccines. J Transl Med 2012;10:154.
175. Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance.
Oncoimmunology 2017;6:e1171447.
176. Ehlers M, Kuebart A, Hautzel H, Enczmann J, Reis AC, Haase M, Allelein S, Dringenberg T, Schmid C, Schott M. Epitope-specific
antitumor immunity suppresses tumor spread in papillary thyroid cancer. J Clin Endocrinol Metab 2017;102:2154-61.
177. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad
Sci 2013;1284:1-5.
178. Zurrida S, Bassi F, Arnone P, Martella S, Del Castillo A, Ribeiro Martini R, Semenkiw ME, Caldarella P. The changing face of
mastectomy (from mutilation to aid to breast reconstruction). Int J Surg Oncol 2011;2011:980158.
179. Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol 2017;44:72-82.
180. Benson JR. The TNM staging system and breast cancer. Lancet Oncol 2003;4:56-60.
181. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-82.
182. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer
2014;14:611-22.
183. Eyles J, Puaux A-L, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prévost-Blondel A, Chow
P, Yang H, Abastado JP. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of
melanoma. J Clin Invest 2010;120:2030-9.
184. Romero I, Garrido F, Garcia-Lora AM. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res
2014;74:6750-7.
185. Manjili MH. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. Cancer Res 2017;77:2564-9.
186. Barkan D, Chambers AF. Prevention of conversion of tumor dormancy into proliferative metastases. In: Cote RJ, Datar RH, editors.
Circulating tumor cells. Current cancer research. New York, NY: Springer New York; 2016. p. 121-37.
187. Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer
immunotherapy. Clin Cancer Res 2016;22:1845-55.
188. Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016;15:235-
47.
189. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell
2015;161:205-14.
190. Hucl T, Gallmeier E, Kern SE. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to
clinical trials. Cell Cycle 2007;6:1336-41.
191. Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 2016;4:56.
192. Saxena M, Bhardwaj N. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin
Immunol 2017;47:35-43.
193. Circelli L, Tornesello M, Buonaguro FM, Buonaguro L. Use of adjuvants for immunotherapy. Hum Vaccines Immunother
2017;13:1774-7.
194. Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 2016;28:329-38.
195. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen
M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined
nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a
multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558-68.
196. Wu Y, Shi H, Jiang M, Qiu M, Jia K, Cao T, Shang Y, Shi L, Jiang K, Wu H. The clinical value of combination of immune checkpoint
inhibitors in cancer patients: a meta-analysis of efficacy and safety. Int J Cancer 2017;141:2562-70.
197. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert
C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Efficacy and safety outcomes in patients with advanced
melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized
phase II and III trials. J Clin Oncol 2017;35:3807-14.
198. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM. Cancer immunotherapy:
opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 2017;81:116-29.
199. Dunn J, Rao S. Epigenetics and immunotherapy: the current state of play. Mol Immunol 2017;87:227-39.
200. Probst P, Kopp J, Oxenius A, Colombo MP, Ritz D, Fugmann T, Neri D. Sarcoma eradication by doxorubicin and targeted TNF relies
+
upon CD8 T-cell recognition of a retroviral antigen. Cancer Res 2017;77:3644-54.
201. Fessler JL, Gajewski TF. The microbiota: a new variable impacting cancer treatment outcomes. Clin Cancer Res 2017;23:3229-31.
202. Li CX, Yu B, Shi L, Geng W, Lin QB, Ling CC, Yang M, Ng KT, Huang JD, Man K. “Obligate” anaerobic Salmonella strain YB1
suppresses liver tumor growth and metastasis in nude mice. Oncol Lett 2017;13:177-83.
203. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug
Discov 2015;14:561-84.
204. Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and
requires careful scheduling to achieve productive immunotherapy. Int J Cancer 2014;134:1695-705.
205. Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C,